« Previous Next » The Journal of Allergy and Clinical Immunology
Volume 122, Issue 2 , Pages 254-260.e7 , August 2008

Asthma and the elite athlete: Summary of the International Olympic Committee's Consensus Conference, Lausanne, Switzerland, January 22-24, 2008

Kenneth D. Fitch, MBBS, MD
- School of Sports Science, Exercise and Health, Faculty of Life Sciences, University of Western Australia, Crawley, Australia
- Reprint requests: Kenneth D. Fitch, MBBS, MD, School of Sports Science, Exercise and Health, Faculty of Life Sciences, University of Western Australia, M408 Crawley, Western Australia.
Malcolm Sue-Chu, MBChB, PhD
- Department of Lung Medicine, St Olavs Hospital, University Hospital of Trondheim, Trondheim, Norway
- Department of Circulation and Imaging, Norwegian University of Science and Technology, Trondheim, Norway
Sandra D. Anderson, PhD, DSc
- Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, Australia
Louis-Philippe Boulet, MD, FCCP, FRCPC
- Institut de Cardiologie et de Pneumologie de l'Université Laval, Hôpital Laval, Laval, Québec, Canada
Robert J. Hancox, MBChB, MD
- Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
- Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand
Donald C. McKenzie, MD, PhD
- Division of Sports Medicine and the School of Human Kinetics, University of British Columbia, Vancouver, British Columbia, Canada
Vibeke Backer, MD, DMSci
- Department of Respiratory Medicine L, Bispebjerg University Hospital, Copenhagen, Denmark
Kenneth W. Rundell, PhD
- Human Physiology Laboratory, Marywood University, Scranton, Pa
Juan M. Alonso, MD
- Medical Department, Royal Spanish Athletics Federation, Madrid, Spain
- Medical and Anti-Doping Commission, International Association of Athletics Federations, Monaco
Pascale Kippelen, PhD
- School of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom
Joseph M. Cummiskey, MD
- Respiratory Medicine, Blackrock Clinic, Dublin, Ireland
Alain Garnier, MD
- World Anti-Doping Agency, Lausanne, Switzerland
Arne Ljungqvist, MD, PhD
- Medical Commission, International Olympic Committee, Lausanne, Switzerland

Received 7 March 2008 ,Revised 3 July 2008 ,Accepted 3 July 2008.

Asthma management for the athlete. BD, Bronchodilator; FVC, forced vital capacity.

Asthma management for the athlete. BD, Bronchodilator; FVC, forced vital capacity.
- Full-Size Image
- Download to PowerPoint
FEV₁ changes before and after exercise challenge and after salbutamol following 1 week of salbutamol or placebo treatment. Error bars represent 95% CIs. The mean FEV₁ is lower after exercise and durin

FEV₁ changes before and after exercise challenge and after salbutamol following 1 week of salbutamol or placebo treatment. Error bars represent 95% CIs. The mean FEV₁ is lower after exercise and during the salbutamol response curve in the salbutamol arm (P < .001). Adapted with permission from Hancox RJ, Subbarao P, Kamada D, Watson RM, Hargreave FE, Inman MD. Beta2-agonist tolerance and exercise-induced bronchospasm. Am J Respir Crit Care Med 2002;165:1068-70.^E39
- Full-Size Image
- Download to PowerPoint
Endurance versus nonendurance Olympic Summer Sports 1996 to 2004 mean percentage β2-agonists notified/approved. #Triathlon, estimate because did not participate in 1996; 29 sports because swimming and

Endurance versus nonendurance Olympic Summer Sports 1996 to 2004 mean percentage β₂-agonists notified/approved. #Triathlon, estimate because did not participate in 1996; 29 sports because swimming and synchronized swimming classed separately from diving and water polo.
- Full-Size Image
- Download to PowerPoint
Percentage of athletes notifying (Sydney) or approved (Salt Lake City, Athens, Torino) for β2-agonist use and the percentage of individual medals won by these athletes at the 2000 to 2006 Olympic Game

Percentage of athletes notifying (Sydney) or approved (Salt Lake City, Athens, Torino) for β₂-agonist use and the percentage of individual medals won by these athletes at the 2000 to 2006 Olympic Games.
- Full-Size Image
- Download to PowerPoint

Consensus Conference supported by the International Olympic Committee.

Disclosure of potential conflict of interest: K. D. Fitch is a member of the International Olympic Committee (IOC) Medical Commission and chair of the IOC Independent Asthma Panel. M. Sue-Chu is on the Advisory Board of Novartis and GlaxoSmithKline, has delivered lectures funded by AstraZeneca, has participated in a clinical trial funded by Novartis, and is a member of the IOC Independent Asthma Panel. S. D. Anderson invented the mannitol test for Pharmaxis Ltd and is a member of the IOC Independent Asthma Panel. L.-P. Boulet has received sponsorship or funding from AstraZeneca, GlaxoSmithKline, Merck Frosst, Schering-Plough, Novartis, Alexion, AsthmaTx, Boehringer-Ingelheim, Ception, Genentech, IVAX, MedImmune, Topigen, and Wyeth. D. C. McKenzie has received research funding from the World Anti-Doping Agency and is a member of the IOC Independent Asthma Panel. V. Backer has received research funding from Pharmaxis Ltd and the Danish Lung Association and is a member of the Advisory Board of MSD, Novartis, ALK-Abelló, AstraZeneca, and GlaxoSmithKline. K. W. Rundell has delivered lectures sponsored by Merck and has received research funding from the World Anti-Doping Agency, Pharmaxis, SkyPharma, and Forest Research. P. Kippelen has received research funding from the British Olympic Association and is a member of the IOC Independent Asthma Panel. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(08)01305-5

doi: 10.1016/j.jaci.2008.07.003

« Previous Next » The Journal of Allergy and Clinical Immunology
Volume 122, Issue 2 , Pages 254-260.e7 , August 2008